Daito Pharmaceutical Co Ltd
TSE:4577

Watchlist Manager
Daito Pharmaceutical Co Ltd Logo
Daito Pharmaceutical Co Ltd
TSE:4577
Watchlist
Price: 2 037 JPY -2.72%
Market Cap: 31.3B JPY
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+21%
Revenue
Forecast
+3%
Operating Income
Forecast
+31%
Net Income
Forecast
+52%

Wall Street
Price Targets

Price Targets Summary
Daito Pharmaceutical Co Ltd

Wall Street analysts forecast Daito Pharmaceutical Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Daito Pharmaceutical Co Ltd is 2 203.2 JPY with a low forecast of 2 181.6 JPY and a high forecast of 2 268 JPY.

Lowest Forecast
Wall Street Target
2 181.6 JPY
7% Upside
Average Forecast
Wall Street Target
2 203.2 JPY
8% Upside
Highest Forecast
Wall Street Target
2 268 JPY
11% Upside
Lowest
Price Target
2 181.6 JPY
7% Upside
Average
Price Target
2 203.2 JPY
8% Upside
Highest
Price Target
2 268 JPY
11% Upside
Daito Pharmaceutical Co Ltd Competitors:
Price Targets
CRDL
Cardiol Therapeutics Inc
563% Upside
S
SBBC
Simply Better Brands Corp
105% Upside
600436
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
36% Upside
688513
Chengdu Easton Biopharmaceuticals Co Ltd
10% Upside
CRDL
Cardiol Therapeutics Inc
563% Upside
S
SBBC
Simply Better Brands Corp
105% Upside
600436
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
36% Upside
688513
Chengdu Easton Biopharmaceuticals Co Ltd
10% Upside
C
1093
CSPC Pharmaceutical Group Ltd
10% Upside
G
512
Grand Pharmaceutical Group Ltd
15% Upside

Revenue
Forecast

Revenue Estimate
Daito Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Daito Pharmaceutical Co Ltd's revenue is 3%. The projected CAGR for the next 3 years is 5%.

3%
Past Growth
5%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Daito Pharmaceutical Co Ltd

Operating Income forecast
is not available for
Daito Pharmaceutical Co Ltd

Net Income
Forecast

Net Income Estimate
Daito Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Daito Pharmaceutical Co Ltd's net income is 3%. The projected CAGR for the next 3 years is -8%.

3%
Past Growth
-8%
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Daito Pharmaceutical Co Ltd's stock price target?
Price Target
2 203.2 JPY

According to Wall Street analysts, the average 1-year price target for Daito Pharmaceutical Co Ltd is 2 203.2 JPY with a low forecast of 2 181.6 JPY and a high forecast of 2 268 JPY.

What is Daito Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
5%

For the last 8 years the compound annual growth rate for Daito Pharmaceutical Co Ltd's revenue is 3%. The projected CAGR for the next 3 years is 5%.

What is Daito Pharmaceutical Co Ltd's Net Income forecast?
Projected CAGR
-8%

For the last 8 years the compound annual growth rate for Daito Pharmaceutical Co Ltd's net income is 3%. The projected CAGR for the next 3 years is -8%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 248,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.